SLC5A2 and Hypoglycemia: Another meta-analysis focusing on the Japanese diabetic population demonstrated that the use of SGLT2 inhibitors was associated with comparable risks of hypoglycemia, urinary tract infections, vaginal infections, hypovolemia, and bone fractures when compared to the placebo [83].